Showing 1,277 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

Why 1 Top Analyst Thinks Gilead Sciences Will Soar More Than 25%

Editor's pick
Motley Fool
24 March 2019
New & experimental HIV treatments

Trogarzo’s Effects on Hard-to-Treat HIV Are Stable Over Two Years

Editor's pick
Poz
20 March 2019
New & experimental HIV treatments

HIV capsid inhibitor may offer long-term viral suppression

News
11 March 2019
Injectable & long-acting HIV treatment

Long-acting injectable treatment maintains viral suppression

News
8 March 2019
New & experimental HIV treatments

HIV Drug Aiming to Free Patients From Daily Doses Nears Market

Editor's pick
Bloomberg
8 March 2019
Side effects

Integrase inhibitor treatment leads to greater weight gain

News
7 March 2019
Child developmental issues

Neural tube defects and integrase inhibitors: still waiting for stronger evidence

News
7 March 2019
The search for a cure

Using anti-cancer immunotherapy to fight HIV

Editor's pick
Eurekalert Medicine & Health
20 February 2019
New & experimental HIV treatments

CytoDyn wins key concession from FDA for flagship HIV drug leronlimab trial

Editor's pick
Proactive Investors USA & Canada
4 February 2019
The search for a cure

Two new types of cell therapy could target reservoir cells and permanently stop HIV infection

News
31 January 2019
Injectable & long-acting HIV treatment

Emerging options: Doctors and advocates discuss treatment and prevention breakthroughs on the horizon

Editor's pick
Positively Aware
30 January 2019
New & experimental HIV treatments

South Africa: New safety concerns emerge on latest HIV wonder drug

Editor's pick
Business Day
18 January 2019
New & experimental HIV treatments

Dolutegravir monotherapy 'not a valid option' for patients with HIV

Editor's pick
Healio
15 January 2019
Side effects

Do integrase inhibitors raise the risk of obesity?

News
10 January 2019
Low CD4 count

‘Left behind’: Drug companies and researchers have overlooked patients who don’t respond to HIV meds

Editor's pick
STAT
8 January 2019
Access to healthcare

Benefits of dolutegravir treatment for all substantially outweigh the risks

News
17 December 2018
Pharmaceutical industry

Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

Editor's pick
BioPharma Dive
12 December 2018
New & experimental HIV treatments

European Commission Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine)

Editor's pick
Merch press release
28 November 2018
New & experimental HIV treatments

Tivicay Plus Boosted Prezista Shows Promise as Two-Drug HIV Regimen

Editor's pick
Poz
16 November 2018
New & experimental HIV treatments

Fostemsavir, novel gp120 inhibitor, salvages nearly half of people with no other treatment options left

News
7 November 2018
Injectable & long-acting HIV treatment

ViiV’s Long-Acting Injectable HIV Regimen Boasts Good 3-Year Results

Editor's pick
Poz
5 November 2018
People with limited treatment options

Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant people shows

News
2 November 2018
Starting treatment

Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA in Treatment-Naïve Adults with HIV-1

Editor's pick
Janssen press release
1 November 2018
Starting treatment

Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Editor's pick
Gilead press release
1 November 2018